title: Thyroid papillary carcinoma after alemtuzumab therapy for MS.
authors.affiliation: Department of Neurology, Southmead Hospital, Bristol, BS10 5NB, UK.
authors.forename: Richard
authors.initials: R
authors.lastname: Ibitoye
authors.forename: Alastair
authors.initials: A
authors.lastname: Wilkins
mesh_terms: D000074323:Alemtuzumab; D061067:Antibodies, Monoclonal, Humanized / Q000009:adverse effects* / Q000627:therapeutic use; D000970:Antineoplastic Agents / Q000009:adverse effects* / Q000627:therapeutic use; D002277:Carcinoma / Q000139:chemically induced* / Q000175:diagnosis; D002291:Carcinoma, Papillary; D005260:Female; D006801:Humans; D008875:Middle Aged; D009103:Multiple Sclerosis / Q000188:drug therapy*; D000077273:Thyroid Cancer, Papillary; D013961:Thyroid Gland / Q000187:drug effects* / Q000473:pathology; D013964:Thyroid Neoplasms / Q000139:chemically induced* / Q000175:diagnosis
chemical_list: D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents; D000074323:Alemtuzumab
references.citation: Cancer Epidemiol Biomarkers Prev. 2009 Mar;18(3):784-91
references.pmid: 19240234
references.citation: Lancet. 2012 Nov 24;380(9856):1819-28
references.pmid: 23122652
references.citation: Thyroid. 2013 Jul;23(7):885-91
references.pmid: 23517343
references.citation: BMJ. 2014 Jun 16;348:g3045
references.pmid: 24935445